Publications
2024
<i>HLA-A</i>*<i>02:01</i>allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of the<i>HLA</i>variation in PDAC
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study.
Turtle, L., Elliot, S., Drake, T. M., Thorpe, M., Khoury, E. G., Greenhalf, W., . . . ISARIC4C Investigators. (2024). Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study.. The Lancet. Oncology, 25(5), 636-648. doi:10.1016/s1470-2045(24)00107-4
Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment.
Overbeek, K. A., Poulsen, J. L., Lanzillotta, M., Vinge-Holmquist, O., Macinga, P., Demirci, A. F., . . . PrescrAIP Study Group. (2024). Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(5), 994-1004.e10. doi:10.1016/j.cgh.2023.12.010
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.
Liew, F., Efstathiou, C., Fontanella, S., Richardson, M., Saunders, R., Swieboda, D., . . . ISARIC investigators. (2024). Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.. Nature immunology, 25(4), 607-621. doi:10.1038/s41590-024-01778-0
Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2024). Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 15(1), 2918. doi:10.1038/s41467-024-47320-6
A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodies.
Costigan, D., Fenn, J., Yen, S., Ilott, N., Bullers, S., Hale, J., . . . Thornton, E. E. (2024). A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodies.. Mucosal immunology, 17(1), 111-123. doi:10.1016/j.mucimm.2023.11.005
Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19.
Devine, K., Russell, C. D., Blanco, G. R., Walker, B. R., Homer, N. Z. M., Denham, S. G., . . . ISARIC4C Investigators and PHOSP-COVID Study Collaborative Group. (2024). Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19.. Clinical endocrinology. doi:10.1111/cen.15012
Accelarated immune ageing is associated with COVID-19 disease severity.
Lord, J. M., Veenith, T., Sullivan, J., Sharma-Oates, A., Richter, A. G., Greening, N. J., . . . ISARIC4C investigators. (2024). Accelarated immune ageing is associated with COVID-19 disease severity.. Immunity & ageing : I & A, 21(1), 6. doi:10.1186/s12979-023-00406-z
Pancreatic and Biliary Tract Cancers: Risk Factors and Etiology, Screening, Surveillance, and Biomarkers of Detection and Prognosis
Ney, A., Osei-Bordom, D. C., Garcia-Sampedro, A., Acedo, P., Fusai, G. K., Stott, M., . . . Pereira, S. P. (2024). Pancreatic and Biliary Tract Cancers: Risk Factors and Etiology, Screening, Surveillance, and Biomarkers of Detection and Prognosis. In Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach (pp. 291-320). doi:10.1002/9781119756422.ch17
2023
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Taquet, M., Skorniewska, Z., Zetterberg, H., Geddes, J. R., Mummery, C. J., Chalmers, J. D., . . . PHOSP-COVID Study Collaborative Group . (2024). Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.. Brain communications, 6(1), fcad357. doi:10.1093/braincomms/fcad357
Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.
Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., . . . ISARIC4C investigators. (2023). Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.. The Journal of infectious diseases, jiad590. doi:10.1093/infdis/jiad590
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2023). Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 14(1), 8487. doi:10.1038/s41467-023-42320-4
Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study
Elneima, O., McAuley, H. J. C., Leavy, O. C., Chalmers, J. D., Horsley, A., Ho, L. -P., . . . Williams, N. (2023). Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study. International Journal of Epidemiology, 53(1). doi:10.1093/ije/dyad165
A multi-country analysis of COVID-19 hospitalizations by vaccination status.
Gonçalves, B. P., Jassat, W., Baruch, J., Hashmi, M., Rojek, A., Dasgupta, A., . . . ISARIC Clinical Characterisation Group. (2023). A multi-country analysis of COVID-19 hospitalizations by vaccination status.. Med (New York, N.Y.), 4(11), 797-812.e2. doi:10.1016/j.medj.2023.08.005
Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis.
Eiseler, K., Neppl, L., Schmidt, A. W., Rauscher, B., Ewers, M., Masson, E., . . . Witt, H. (2023). Genetic and functional analysis of chymotrypsin-like protease (CTRL) in chronic pancreatitis.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 23(8), 957-963. doi:10.1016/j.pan.2023.11.002
Long COVID research: an update from the PHOSP-COVID Scientific Summit.
Brightling, C. E., Evans, R. A., Singapuri, A., Smith, N., Wain, L. V., & PHOSP-COVID Collaborative Group. (2023). Long COVID research: an update from the PHOSP-COVID Scientific Summit.. The Lancet. Respiratory medicine, 11(11), e93-e94. doi:10.1016/s2213-2600(23)00341-7
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.
C-MORE/PHOSP-COVID Collaborative Group. (2023). Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.. The Lancet. Respiratory medicine, S2213-2600(23)00262-X. doi:10.1016/s2213-2600(23)00262-x
Liver injury in hospitalized patients with COVID-19: An International observational cohort study.
Tirupakuzhi Vijayaraghavan, B. K., Bishnu, S., Baruch, J., Citarella, B. W., Kartsonaki, C., Meeyai, A., . . . ISARIC Clinical Characterisation Group. (2023). Liver injury in hospitalized patients with COVID-19: An International observational cohort study.. PloS one, 18(9), e0277859. doi:10.1371/journal.pone.0277859
Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.
Roper, K. J., Thomas, J., Albalawi, W., Maddocks, E., Dobson, S., Alshehri, A., . . . Pollakis, G. (2023). Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.. Scientific reports, 13(1), 15014. doi:10.1038/s41598-023-41928-2
A second update on mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative. (2023). A second update on mapping the human genetic architecture of COVID-19.. Nature, 621(7977), E7-E26. doi:10.1038/s41586-023-06355-3
Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19
Wainstein, M., Spyrison, N., Dai, D., Ghadimi, M., Chávez-Iñiguez, J. S., Rizo-Topete, L., . . . Zucman, D. (2023). Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19. Kidney International Reports, 8(8), 1514-1530. doi:10.1016/j.ekir.2023.05.015
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
Jackson, C., Stewart, I., Plekhanova, T., Cunningham, P. S., Hazel, A. L., Al-Sheklly, B., . . . PHOSP-COVID, S. C. G. (2023). Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. LANCET RESPIRATORY MEDICINE, 11(8), 673-684. doi:10.1016/S2213-2600(23)00124-8
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (vol 617, pg 764, 2023)
Pairo-Castineira, E., Rawlik, K., Bretherick, A. D., Qi, T., Wu, Y., Nassiri, I., . . . Baillie, J. K. (2023). GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (vol 617, pg 764, 2023). NATURE. doi:10.1038/s41586-023-06383-z
Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.
Katona, B. W., Klute, K., Brand, R. E., Everett, J. N., Farrell, J. J., Hawthorne, K., . . . PRECEDE Consortium. (2023). Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.. Cancer prevention research (Philadelphia, Pa.), 16(6), 343-352. doi:10.1158/1940-6207.capr-22-0529
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer
Campa, D., Gentiluomo, M., Stein, A., Aoki, M. N., Oliverius, M., Vodickova, L., . . . Canzian, F. (2023). The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 186. doi:10.1016/j.critrevonc.2023.104020
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Quinn, L. M., Haldenby, S., Antzcak, P., Fowler, A., Bullock, K., Kenny, J., . . . Goldring, C. (n.d.). Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports, 13(1). doi:10.1038/s41598-023-33096-0
Validation of extracorporeal membrane oxygenation mortality prediction and severity of illness scores in an international COVID-19 cohort.
Shah, N., Xue, B., Xu, Z., Yang, H., Marwali, E., Dalton, H., . . . ISARIC Clinical Characterisation Group. (2023). Validation of extracorporeal membrane oxygenation mortality prediction and severity of illness scores in an international COVID-19 cohort.. Artificial organs. doi:10.1111/aor.14542
Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.c.6511738
Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Data from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.c.6511738.v1
Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424323
Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424323.v1
Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424320
Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424320.v1
Supplementary Figure 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Figure 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424317
Supplementary Figure 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Figure 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424317.v1
Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424314.v1
Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424314
Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424311
Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 2 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424311.v1
Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424308
Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424308.v1
Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424305
Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2023). Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. doi:10.1158/0008-5472.22424305.v1
Genetic and non-genetic risk factors for early-onset pancreatic cancer.
Nodari, Y., Gentiluomo, M., Mohelnikova-Duchonova, B., Kreivenaite, E., Milanetto, A. C., Skieceviciene, J., . . . Campa, D. (2023). Genetic and non-genetic risk factors for early-onset pancreatic cancer.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, S1590-8658(23)00514-5. doi:10.1016/j.dld.2023.02.023
Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
Ferguson, R., Aughton, K., Evans, A., Shaw, V., Armstrong, J., Ware, A., . . . Greenhalf, W. (2023). Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. CURRENT ISSUES IN MOLECULAR BIOLOGY, 45(3), 2505-2520. doi:10.3390/cimb45030164
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5
The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer
Ahmed, A. A., Greenhalf, W., Palmer, D. H., Williams, N., Worthington, J., Arshad, T., . . . Neidle, S. (2023). The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. MOLECULES, 28(6). doi:10.3390/molecules28062452
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
de Andres, M. P., Jackson, R. J., Felipe, I., Zagorac, S., Pilarsky, C., Schlitter, A. M., . . . Real, F. X. (2023). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. GUT, 72(3), 535-548. doi:10.1136/gutjnl-2021-325803
Wild-type N-Ras Complements Mutant K-Ras in Pancreatic Cancer Cell Lines but K-Ras has a Specific Role in Cell Cycle Independent Regulation of G2 Cyclins
Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning
Nene, N. R. R., Ney, A., Nazarenko, T., Blyuss, O., Johnston, H. E. E., Whitwell, H. J. J., . . . Timms, J. F. F. (2023). Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. COMMUNICATIONS MEDICINE, 3(1). doi:10.1038/s43856-023-00237-5
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402
2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Donovan-Banfield, I., Penrice-Randal, R., Goldswain, H., Rzeszutek, A. M., Pilgrim, J., Bullock, K., . . . Fletcher, T. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-34839-9
Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset.
Gentiluomo, M., Capurso, G., Morelli, L., Ermini, S., Pasquali, C., Latiano, A., . . . Campa, D. (2022). Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset.. Neuroendocrinology, 112(12), 1168-1176. doi:10.1159/000524659
Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.
Baruch, J., Rojek, A., Kartsonaki, C., Vijayaraghavan, B. K. T., Gonçalves, B. P., Pritchard, M. G., . . . ISARIC Clinical Characterisation Group. (2022). Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.. Influenza and other respiratory viruses, 16(6), 1040-1050. doi:10.1111/irv.13039
Wild-type N-Ras Complements Mutant K-Ras in Pancreatic Cancer Cell Lines but K-Ras has a Specific Role in Cell Cycle Independent Regulation of G2 Cyclins
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2
United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer
Oldfield, L., Stott, M., Hanson, R., Jackson, R. J., Reynolds, W., Chandran-Gorner, V., . . . Costello, E. (2022). United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ OPEN, 12(10). doi:10.1136/bmjopen-2022-068010
Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study
Vink, E., Davis, C., MacLean, A., Pascall, D., McDonald, S. E., Gunson, R., . . . Ho, A. (2022). Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac531
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Siggins, M. K., Davies, K., Fellows, R., Thwaites, R. S., Baillie, J. K., Semple, M. G., . . . ISARIC4C Investigators. (2022). Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology. doi:10.1111/imm.13585
Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study
Reyes, L. F., Murthy, S., Garcia-Gallo, E., Merson, L., Ibanez-Prada, E. D., Rello, J., . . . Olliaro, P. L. (2022). Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study. CRITICAL CARE, 26(1). doi:10.1186/s13054-022-04155-1
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Keeling, M. J., Dyson, L., Guyver-Fletcher, G., Holmes, A., Semple, M. G., Tildesley, M. J., & Hill, E. M. (2022). Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. STATISTICAL METHODS IN MEDICAL RESEARCH, 31(9), 1716-1737. doi:10.1177/09622802211070257
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
Evans, R. A., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H. J. C., Shikotra, A., . . . Brightling, C. E. (2022). Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. LANCET RESPIRATORY MEDICINE, 10(8), 761-775. doi:10.1016/S2213-2600(22)00127-8
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study
Millar, J. E., Neyton, L., Seth, S., Dunning, J., Merson, L., Murthy, S., . . . Baillie, J. K. (2022). Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-08032-3
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
Narhi, F., Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., . . . Docherty, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. LANCET DIGITAL HEALTH, 4(4). Retrieved from https://www.webofscience.com/
Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium.
Gonda, T. A., Farrell, J., Wallace, M., Khanna, L., Janec, E., Kwon, R., . . . PRECEDE Consortium. (2022). Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium.. Gastrointestinal endoscopy, 95(4), 723-732.e7. doi:10.1016/j.gie.2021.10.025
Linking COVID-19 and Acute Pancreatitis Through the Pathogenic Effects of the SARS-CoV-2 S Protein Subunit 1 on Pancreatic Stellate Cells and Macrophages
Neoptolemos, J. P., & Greenhalf, W. (2022). Linking COVID-19 and Acute Pancreatitis Through the Pathogenic Effects of the SARS-CoV-2 S Protein Subunit 1 on Pancreatic Stellate Cells and Macrophages. FUNCTION, 3(2). doi:10.1093/function/zqac009
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes
Oldfield, L., Evans, A., Rao, R. G., Jenkinson, C., Purewal, T., Psarelli, E. E., . . . Costello, E. (2022). Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBIOMEDICINE, 75. doi:10.1016/j.ebiom.2021.103802
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol
Knight, S. R., Gupta, R. K., Ho, A., Pius, R., Buchan, I., Carson, G., . . . Harrison, E. M. (2022). Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77(6), 606-615. doi:10.1136/thoraxjnl-2021-217629
2021
Mapping the human genetic architecture of COVID-19
Niemi, M. E. K., Karjalainen, J., Daly, M., Ganna, A., Mehtonen, J., Cordioli, M., . . . Dopazo, X. (2021). Mapping the human genetic architecture of COVID-19. NATURE, 600(7889), 472-+. doi:10.1038/s41586-021-03767-x
Early detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on a panel of protein serum biomarkers
Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk
Lu, Y., Gentiluomo, M., Macauda, A., Gioffreda, D., Gazouli, M., Petrone, M. C., . . . Canzian, F. (2021). Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.771312
Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium.
Gonda, T. A., Everett, J. N., Wallace, M., Simeone, D. M., & PRECEDE Consortium. (2021). Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium.. Gastroenterology, 161(6), 1751-1757. doi:10.1053/j.gastro.2021.08.036
The value of open-source clinical science in pandemic response: lessons from ISARIC
The value of open-source clinical science in pandemic response: lessons from ISARIC (2021). LANCET INFECTIOUS DISEASES, 21(12), 1623-1624. doi:10.1016/S1473-3099(21)00565-X
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
de, S. T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, N. S., . . . Dong, T. (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. ISCIENCE, 24(11). doi:10.1016/j.isci.2021.103353
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. CANCERS, 13(22). doi:10.3390/cancers13225758
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318
Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study
Rosato, V., Gomez-Rubio, P., Molina-Montes, E., Marquez, M., Lohr, M., O'Rorke, M., . . . Investigators, P. S. (2021). Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. EUROPEAN JOURNAL OF CANCER PREVENTION, 30(6), 423-430. doi:10.1097/CEJ.0000000000000588
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
Evans, R. A., McAuley, H., Harrison, E. M., Shikotra, A., Singapuri, A., Sereno, M., . . . Brightling, C. E. (2021). Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. LANCET RESPIRATORY MEDICINE, 9(11), 1275-1287. doi:10.1016/S2213-2600(21)00383-0
A prenylated dsRNA sensor protects against severe COVID-19
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study
Abdukahil, S. A., Abe, R., Abel, L., Absil, L., Acker, A., Adachi, S., . . . Zucman, D. (2021). COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. INFECTION, 49(5), 889-905. doi:10.1007/s15010-021-01599-5
Genetic polymorphisms involved in mitochondrial metabolism and pancreatic cancer risk.
Peduzzi, G., Gentiluomo, M., Tavano, F., Arcidiacono, P. G., Ermini, S., Vodicka, P., . . . Campa, D. (2021). Genetic polymorphisms involved in mitochondrial metabolism and pancreatic cancer risk.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. doi:10.1158/1055-9965.epi-21-0353
LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK
Palmieri, C., Turtle, L., Drake, T., Harrison, E., Docherty, A., Greenhalf, B., . . . Semple, M. M. G. (2021). LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 32 (pp. S1337).
Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK
Vaselli, N. M., Setiabudi, W., Subramaniam, K., Adams, E. R., Turtle, L., Iturriza-Gomara, M., . . . Hungerford, D. (2021). Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK. BMC INFECTIOUS DISEASES, 21(1). doi:10.1186/s12879-021-06443-7
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2
Concordance of human equilibrative nucleoside transporter‐1 expressions between murine ( 10D7G2 ) and rabbit ( SP120 ) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial
Okamura, Y., Boku, N., Ghaneh, P., Greenhalf, W., Yasukawa, S., Narimatsu, H., . . . Uesaka, K. (2021). Concordance of human equilibrative nucleoside transporter‐1 expressions between murine ( 10D7G2 ) and rabbit ( SP120 ) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. Cancer Reports. doi:10.1002/cnr2.1507
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol
McCarthy, C., Sacco, J., Fedele, S., Ho, M., Porter, S., Liloglou, T., . . . Shaw, R. (2021). SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. TRIALS, 22(1). doi:10.1186/s13063-021-05373-8
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK
Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.
Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1
Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8
Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-x
Going viral: misinformation in the time of COVID-19
Going viral: misinformation in the time of COVID-19 (2021). LANCET RHEUMATOLOGY, 3(6), E393. doi:10.1016/S2665-9913(21)00104-1
Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction
Galeotti, A. A., Gentiluomo, M., Rizzato, C., Obazee, O., Neoptolemos, J. P., Pasquali, C., . . . Campa, D. (2021). Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. JOURNAL OF MEDICAL GENETICS, 58(6), 369-377. doi:10.1136/jmedgenet-2020-106961
The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements
Ashworth, M., Small, B., Oldfield, L., Evans, A., Greenhalf, W., Halloran, C., & Costello, E. (2021). The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements. SCIENTIFIC REPORTS, 11(1). doi:10.1038/s41598-021-85052-5
Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol
Setiabudi, W., Hungerford, D., Subramaniam, K., Vaselli, N. M., Shaw, V. E., Wilton, M., . . . French, N. (2021). Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. BMJ Open, 11(3), e048317. doi:10.1136/bmjopen-2020-048317
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Lopez de Maturana, E., Rodriguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martin-Antoniano, I. A., . . . Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. GENOME MEDICINE, 13(1). doi:10.1186/s13073-020-00816-4
Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses
Molina-Montes, E., Coscia, C., Gomez-Rubio, P., Fernandez, A., Boenink, R., Rava, M., . . . Malats, N. (2021). Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. GUT, 70(2), 319-329. doi:10.1136/gutjnl-2019-319990
Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials.
Grant, R. C., Duan, K., Jackson, R., Greenhalf, W., Costello-Goldring, E., Ghaneh, P., . . . Fischer, S. (2021). Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials.. In CANCER RESEARCH Vol. 81. Retrieved from https://www.webofscience.com/
2020
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study
Debernardi, S., O'Brien, H., Algahmdi, A. S., Malats, N., Stewart, G. D., Pljesa-Ercegovac, M., . . . Crnogorac-Jurcevic, T. (2020). A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLOS MEDICINE, 17(12). doi:10.1371/journal.pmed.1003489
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., . . . Costello, E. (2020). Early detection of pancreatic cancer. The Lancet Gastroenterology and Hepatology, 5(7), 698-710. doi:10.1016/S2468-1253(19)30416-9
Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2020). Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.. Cancer Research, 80(13), 2861-2873. doi:10.1158/0008-5472.can-19-3534
Blood Levels of Adiponectin and IL-1Ra Could Facilitate Earlier Detection of PDAC by Distinguishing Individuals With Type 3c Diabetes From Those With Type 2 Diabetes
Oldfield, L., Rao, R., Purewal, T., Greenhalf, W., Halloran, C., & Costello, E. (2019). Blood Levels of Adiponectin and IL-1Ra Could Facilitate Earlier Detection of PDAC by Distinguishing Individuals With Type 3c Diabetes From Those With Type 2 Diabetes. In PANCREAS Vol. 48 (pp. 1502). Retrieved from https://www.webofscience.com/
International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club
Greenhalf, W., Lévy, P., Gress, T., Rebours, V., Brand, R. E., Pandol, S., . . . Neoptolemos, J. (2020). International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. doi:10.1016/j.pan.2020.05.011
Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships
Molina-Montes, E., Van Hoogstraten, L., Gomez-Rubio, P., Lohr, M., Sharp, L., Molero, X., . . . Malats, N. (2020). Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(5), 1009-1018. doi:10.1158/1055-9965.EPI-19-1027
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (vol 10, 1796, 2020)
McWilliam, S. J., Rosala-Hallas, A., Jones, A. P., Shaw, V., Greenhalf, W., Jaki, T., . . . Pirmohamed, M. (2020). A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (vol 10, 1796, 2020). SCIENTIFIC REPORTS, 10(1). doi:10.1038/s41598-020-61783-9
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.
McWilliam, S. J., Rosala-Hallas, A., Jones, A. P., Shaw, V., Greenhalf, W., Jaki, T., . . . Pirmohamed, M. (2020). A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.. Scientific reports, 10(1). doi:10.1038/s41598-020-58790-1
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
Mahajan, U. M., Goni, E., Langhoff, E., Li, Q., Costello, E., Greenhalf, W., . . . Mayerle, J. (2020). Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI CANCER SPECTRUM, 4(1). doi:10.1093/jncics/pkz060
2019
Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort
Schwartz, M., Korenbaum, C., Benfoda, M., Mary, M., Colas, C., Coulet, F., . . . Hammel, P. (2019). Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. CLINICAL GENETICS, 96(6), 579-584. doi:10.1111/cge.13629
Natural history of SPINK1 germline mutation related-pancreatitis
Muller, N., Sarantitis, I., Rouanet, M., de Mestier, L., Halloran, C. M., & Greenhalf, W. (2019). Natural history of SPINK1 germline mutation related-pancreatitis. EBioMedicine, 48, 581-591. doi:10.1016/j.ebiom.2019.09.032
Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic
Olesen, S. S., Krarup, H., Poulsen, J. L., Christensen, J. H., Sheel, A. R. G., Sutton, R., . . . Drewes, A. M. (2019). Pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis: New insights on an old topic. United European Gastroenterology Journal. doi:10.1177/2050640619846011
Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
Campa, D., Matarazzi, M., Greenhalf, W., Bijlsma, M., Saum, K. -U., Pasquali, C., . . . Canzian, F. (2019). Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. INTERNATIONAL JOURNAL OF CANCER, 144(6), 1275-1283. doi:10.1002/ijc.31928
Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches
Gomez-Rubio, P., Pinero, J., Molina-Montes, E., Gutierrez-Sacristan, A., Marquez, M., Rava, M., . . . Investigators, P. S. (2019). Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. INTERNATIONAL JOURNAL OF CANCER, 144(7), 1540-1549. doi:10.1002/ijc.31866
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.
Sheel, A. R. G., Harrison, S., Sarantitis, I., Nicholson, J. A., Hanna, T., Grocock, C., . . . Greenhalf, W. (2019). Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.. The American Journal of Gastroenterology (Elsevier), 114(1), 155-164. doi:10.1038/s41395-018-0395-y
Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework
Yap, C., Kong, A., Slade, D., Jackson, R., Savage, J., Sanghera, P., . . . Palmieri, C. (2019). Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework. In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/
hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer
Hale, J., Evans, A., Aughton, K., Elander, N. O., Ghaneh, P., Neoptolemos, J. P., . . . Greenhalf, W. (2019). hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer. In PANCREAS Vol. 48 (pp. 1436-1437). Retrieved from https://www.webofscience.com/
2018
S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes
Nedjadi, T., Evans, A., Sheikh, A., Barerra, L., Al-Ghamdi, S., Oldfield, L., . . . Costello, E. (2018). S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. BMC CANCER, 18. doi:10.1186/s12885-018-5161-4
Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma
Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C. M., . . . Mayerle, J. (2018). Immune Cell and Stromal Signature Associated with Progression-free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 155(05), 1625-1639.E2. doi:10.1053/j.gastro.2018.08.009
ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma
Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O., Ma, Y. T., . . . Bridgewater, J. (2018). ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/
Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.
Martinez-Bosch, N., Barranco, L. E., Orozco, C. A., Moreno, M., Visa, L., Iglesias, M., . . . Navarro, P. (2018). Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.. Oncotarget, 9(68), 32984-32996. doi:10.18632/oncotarget.26034
Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms (vol 39, pg 360, 2018)
Obazee, O., Capurso, G., Tavano, F., Archibugi, L., De Bonis, A., Greenhalf, W., . . . Campa, D. (2018). Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms (vol 39, pg 360, 2018). CARCINOGENESIS, 39(7), 969. doi:10.1093/carcin/bgy067
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018). Therapeutic developments in pancreatic cancer: current and future perspectives. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 15(6), 333-348. doi:10.1038/s41575-018-0005-x
PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.
Evans, M., Knott, S., Hurt, C., Patterson, J., Robinson, M., Hutcheson, K. A., . . . Jones, T. (2018). PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.TPS6097
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Canc, E. S. G. P. (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118, 1084-1088. doi:10.1038/s41416-018-0005-1
Development of Novel Therapeutic Response Biomarkers
Elander, N., Aughton, K., & Greenhalf, W. (2018). Development of Novel Therapeutic Response Biomarkers. In Pancreatic Cancer (pp. 1273-1304). Springer New York. doi:10.1007/978-1-4939-7193-0_59
Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma
Sheel, A., Nicholson, J., Sarantitis, I., Neoptolemos, J. P., & Greenhalf, W. (2018). Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. In Pancreatic Cancer (pp. 1401-1434). Springer New York. doi:10.1007/978-1-4939-7193-0_63
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.
Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., . . . Greenhalf, W. (2018). Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predict survival in pancreatic cancer.. British Journal of Cancer, 118(7), 947-954. doi:10.1038/s41416-018-0004-2
Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives
Molina-Montes, E., Gomez-Rubio, P., Marquez, M., Rava, M., Lohr, M., Michalski, C. W., . . . Investigators, P. S. (2018). Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 47(2), 473-483. doi:10.1093/ije/dyx269
Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms
Obazee, O., Capurso, G., Tavano, F., Archibugi, L., De Bonis, A., Greenhalf, W., . . . Campa, D. (2018). Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. CARCINOGENESIS, 39(3), 360-367. doi:10.1093/carcin/bgx150
Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer
Bauer, A. S., Nazarov, P. V., Giese, N. A., Beghelli, S., Heller, A., Greenhalf, W., . . . Hoheisel, J. D. (2018). Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. INTERNATIONAL JOURNAL OF CANCER, 142(5), 1010-1021. doi:10.1002/ijc.31087
ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.
Palmer, D. H., Ross, P. J., Silcocks, P., Greenhalf, W., Faluyi, O. O., Ma, Y. T., . . . Neoptolemos, J. P. (2018). ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.4_suppl.TPS537
Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial
Halloran, C. M. (2018). Cytoplasmic HuR Status Predicts Disease-Free Survival in Resected Pancreatic Cancer: A Post-Hoc Analysis from the International Multi-Institutional Phase III ESPAC-3 Clinical Trial. Annals of Surgery, 267(2), 364-369. doi:10.1097/SLA.0000000000002088
Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
Campa, D., Pastore, M., Capurso, G., Hackert, T., Di Leo, M., Izbicki, J. R., . . . Canzian, F. (2018). Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. INTERNATIONAL JOURNAL OF CANCER, 142(2), 290-296. doi:10.1002/ijc.31047
Pancreatic ductal adenocarcinoma is associated with high prevalence of pancretogenic diabetes mellitus in individuals with potentially resectable disease.
Rao, R. G., Oldfield, L., Evans, A., Greenhalf, W., Halloran, C., & Costello, E. (2018). Pancreatic ductal adenocarcinoma is associated with high prevalence of pancretogenic diabetes mellitus in individuals with potentially resectable disease.. In BRITISH JOURNAL OF SURGERY Vol. 105 (pp. 82). Retrieved from https://www.webofscience.com/
2017
Detecting Pancreatic Cancer Earlier: Identifying Type 3c Diabetes in Individuals Newly Diagnosed With Type 2 Diabetes
Oldfield, L., Rao, R., Purewal, T., Neoptolemos, J. P., Halloran, C. M., Greenhalf, W., & Costello, E. (2017). Detecting Pancreatic Cancer Earlier: Identifying Type 3c Diabetes in Individuals Newly Diagnosed With Type 2 Diabetes. In PANCREAS Vol. 46 (pp. 1425). Retrieved from https://www.webofscience.com/
Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent
Williams, D., Gana, T., Sivapalan, L., Butler, O., Jackson, R., Perez-Mancera, P., . . . Costello, E. (2017). Nrf2 in Pancreatic Cancer Chemotherapy Response and the Use of Brusatol as a Chemotherapeutic Agent. In PANCREAS Vol. 46 (pp. 1443). Retrieved from http://gateway.webofknowledge.com/
The Prevalence of Diabetes Mellitus is Significantly Higher for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma Compared to Surgery for Other Pancreatic Pathologies
Rao, R. G., Costello, E., Halloran, C. M., Oldfield, L., Greenhalf, W., Ghaneh, P., . . . Mann, K. (2017). The Prevalence of Diabetes Mellitus is Significantly Higher for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma Compared to Surgery for Other Pancreatic Pathologies. In PANCREAS Vol. 46 (pp. 1403-1404). Retrieved from https://www.webofscience.com/
THE PROTEKT STUDY - A PHASE IIA, RANDOMISED, CONTROLLED, OPEN-LABEL TRIAL OF ROSUVASTATIN FOR THE PREVENTION OF AMINOGLYCOSIDE-INDUCED KIDNEY TOXICITY IN CHILDREN WITH CYSTIC FIBROSIS
McWilliam, S. J., Antoine, D. J., Rosala-Hallas, A., Jones, A., MacLean, C., Prayle, A., . . . Pirmohamed, M. (2017). THE PROTEKT STUDY - A PHASE IIA, RANDOMISED, CONTROLLED, OPEN-LABEL TRIAL OF ROSUVASTATIN FOR THE PREVENTION OF AMINOGLYCOSIDE-INDUCED KIDNEY TOXICITY IN CHILDREN WITH CYSTIC FIBROSIS. In PEDIATRIC PULMONOLOGY Vol. 52 (pp. S353). Indiana Convention Center, Indianapolis, Indiana. doi:10.1002/ppul.23840
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Martinelli, P., Pau, E. C. D. S., Cox, T., Sainz, B., Dusetti, N., Greenhalf, W., . . . Real, F. X. (2017). GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66(9), 1665-1676. doi:10.1136/gutjnl-2015-311256
Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium
Campa, D., Obazee, O., Pastore, M., Panzuto, F., Lico, V., Greenhalf, W., . . . Canzian, F. (2017). Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 26(8), 1349-1351. doi:10.1158/1055-9965.EPI-17-0075
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis
Liu, T., Huang, W., Szatmary, P., Abrams, S. T., Alhamdi, Y., Lin, Z., . . . Toh, C. H. (2017). Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis. BRITISH JOURNAL OF SURGERY, 104(9), 1215-1225. doi:10.1002/bjs.10538
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
Gomez-Rubio, P., Rosato, V., Marquez, M., Bosetti, C., Molina-Montes, E., Rava, M., . . . Malats, N. (2017). A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. ANNALS OF ONCOLOGY, 28(7), 1618-1624. doi:10.1093/annonc/mdx167
DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists
Jandaghi, P., Najafabadi, H. S., Bauer, A., Papadakis, A. I., Fassan, M., Hall, A., . . . Hoheisel, J. D. (2017). DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.AM2017-1135
Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.
Neoptolemos, J. P., Palmer, D., Greenhalf, W., Ghaneh, P., Jackson, R., Evans, A., . . . Middleton, G. W. (2017). Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.4104
Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer
Totti, S., Vernardis, S. I., Meira, L., Perez-Mancere, P. A., Costello, E., Greenhalf, W., . . . Velliou, E. G. (2017). Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer. DRUG DISCOVERY TODAY, 22(4), 690-701. Retrieved from https://www.webofscience.com/
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., . . . Neoptolemos, J. P. (2017). Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18(4), 486-499. doi:10.1016/S1470-2045(17)30084-0
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
Bird, N. T. E., Elmasry, M., Jones, R., Psarelli, E., Dodd, J., Malik, H., . . . Palmer, D. (2017). Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. BRITISH JOURNAL OF SURGERY, 104(4), 328-336. doi:10.1002/bjs.10482
Reduced risk of pancreatic cancer associated with asthma and nasal allergies
Gomez-Rubio, P., Zock, J. -P., Rava, M., Marquez, M., Sharp, L., Hidalgo, M., . . . Investigators, P. S. (2017). Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut, 66(2), 314-322. doi:10.1136/gutjnl-2015-310442
2016
Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice
Jandaghi, P., Najafabadi, H. S., Bauer, A. S., Papadakis, A. I., Fassan, M., Hall, A., . . . Hoheisel, J. D. (2016). Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, 151(6), 1218-1231. doi:10.1053/j.gastro.2016.08.040
Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis
Fjeld, K., Beer, S., Johnstone, M., Zimmer, C., Moessner, J., Ruffert, C., . . . Rosendahl, J. (2016). Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. PLOS ONE, 11(11). doi:10.1371/journal.pone.0165567
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., . . . Gallinger, S. (2016). Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.. JAMA oncology, 3(6), 774-783. doi:10.1001/jamaoncol.2016.3916
The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., . . . Neoptolemos, J. P. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. BRITISH JOURNAL OF CANCER, 115(7), 887-894. doi:10.1038/bjc.2016.277
Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression
Botla, S. K., Savant, S., Jandaghi, P., Bauer, A. S., Mucke, O., Moskalev, E. A., . . . Hoheisel, J. D. (2016). Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Research, 76(14), 4149-4159. doi:10.1158/0008-5472.CAN-15-0390
A Personalized Approach to Adjuvant Therapy: Cytoplasmic HuR Status Predicts Disease Free Survival After Resection for Pancreatic Ductal Adenocarcinoma
Tatarian, T., Grigoli, A., Leiby, B. E., Jimbo, M., Dabbish, N., Jiang, W., . . . Brody, J. R. (2016). A Personalized Approach to Adjuvant Therapy: Cytoplasmic HuR Status Predicts Disease Free Survival After Resection for Pancreatic Ductal Adenocarcinoma. In GASTROENTEROLOGY Vol. 150 (pp. S1211). doi:10.1016/S0016-5085(16)34095-1
Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus
Jenkinson, C., Elliott, V., Evans, A., Oldfield, L., Jenkins, R., O'Brien, D., . . . Costello-Goldring, E. (2016). Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clinical Cancer Research, 22(7), 1734-1743. doi:10.1158/1078-0432.ccr-15-0879
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Middleton, G., Greenhalf, W., Costello, E., Shaw, V., Cox, T., Ghaneh, P., . . . Neoptolemos, J. P. (2016). Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 114, 510-518. doi:10.1038/bjc.2015.468
Xanthogranulomatous pancreatitis associated with a mucinous cystic neoplam
Hanna, T., Abdul-Rahman, Z., Greenhalf, W., Farooq, A., & Neoptolemos, J. P. (2016). Xanthogranulomatous pancreatitis associated with a mucinous cystic neoplam. PATHOLOGY INTERNATIONAL, 66(3), 174-176. doi:10.1111/pin.12356
Choline Kinase Alpha (CHK alpha) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Mazarico, J. M., Sanchez-Arevalo Lobo, V. J., Favicchio, R., Greenhalf, W., Costello, E., Carrillo-de Santa Pau, E., . . . Real, F. X. (2016). Choline Kinase Alpha (CHK alpha) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. MOLECULAR CANCER THERAPEUTICS, 15(2), 323-333. doi:10.1158/1535-7163.MCT-15-0214
UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis
Abu-Alainin, W., Gana, T., Liloglou, L., Olayanju, A., Barrera Briceno, L., Ferguson, R., . . . Costello-Goldring, E. (2016). UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. Journal of Pathology, 238(3), 423-433. doi:10.1002/path.4665
Accurate Admission Transcriptomic Signature of the Severity of Acute Pancreatitis
Nunes, Q. M., Lane, B., Huang, W., Altaf, K., Rainbow, L., Armstrong, J., . . . Sutton, R. (2016). Accurate Admission Transcriptomic Signature of the Severity of Acute Pancreatitis. In PANCREAS (Vol. 45, Iss. 10, pp. 1530). Retrieved from https://www.webofscience.com/
Changes in the Expression of RRM Subunits Induce Gemcitabine Resistance in a Growth Dependent Manner
Mann, K. S., Brumskill, S., Ghaneh, P., & Greenhalf, W. (2016). Changes in the Expression of RRM Subunits Induce Gemcitabine Resistance in a Growth Dependent Manner. PANCREAS, 45(10), 1523. Retrieved from https://www.webofscience.com/
Exploring the Protein Profile of Pancreatic Cancer-Associated Diabetes
Oldfield, L., Jenkinson, C., Purewal, T., Sutton, R., Neoptolemos, J. P., Greenhalf, W., & Costello, E. (2016). Exploring the Protein Profile of Pancreatic Cancer-Associated Diabetes. PANCREAS, 45(10), 1531-1532. Retrieved from https://www.webofscience.com/
Single-Nucleotide Polymorphism to Associate Cancer Risk
Shaw, V., Bullock, K., & Greenhalf, W. (2016). Single-Nucleotide Polymorphism to Associate Cancer Risk. CANCER GENE PROFILING, 1381, 93-110. doi:10.1007/978-1-4939-3204-7_6
2015
<i>TERT</i> gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, D., Rizzato, C., Stolzenberg-Solomon, R., Pacetti, P., Vodicka, P., Cleary, S. P., . . . Canzian, F. (2015). <i>TERT</i> gene harbors multiple variants associated with pancreatic cancer susceptibility. INTERNATIONAL JOURNAL OF CANCER, 137(9), 2175-2183. doi:10.1002/ijc.29590
Actinomycin D Sensitizes Chemotherapy Resistant Suit-2 Pancreatic Cancer Cell Lines to Gemcitabine
Mann, K., Rogoyski, B., Ghaneh, P., Rubbi, C., & Greenhalf, W. (2015). Actinomycin D Sensitizes Chemotherapy Resistant Suit-2 Pancreatic Cancer Cell Lines to Gemcitabine. Pancreas, 44(8), 1395-1396. Retrieved from https://journals.lww.com/
Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Radon, T. P., Massat, N. J., Jones, R., Alrawashdeh, W., Dumartin, L., Ennis, D., . . . Crnogorac-Jurcevic, T. (2015). Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. CLINICAL CANCER RESEARCH, 21(15), 3512-3521. doi:10.1158/1078-0432.CCR-14-2467
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Cioffi, M., Trabulo, S., Hidalgo, M., Costello, E., Greenhalf, W., Erkan, M., . . . Heeschen, C. (2015). Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 21(10), 2325-2337. doi:10.1158/1078-0432.CCR-14-1399
Biomarkers for early diagnosis of pancreatic cancer
Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, B., . . . Costello-Goldring, E. (2015). Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology & Hepatology, 9(03), 305-315. doi:10.1586/17474124.2015.965145
Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer
Jenkinson, C., Elliott, V., Menon, U., Apostolidou, S., Fourkala, O. E., Gentry-Maharaj, A., . . . Costello, E. (2015). Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. JOURNAL OF PROTEOMICS, 113, 400-402. doi:10.1016/j.jprot.2014.10.001
A Single p53 Mutation May Predict Survival in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Nicholson, J., Howes, N., Harrison, S., Hanna, T., Yan, L., Lane, B., . . . Greenhalf, W. (2015). A Single p53 Mutation May Predict Survival in Intraductal Papillary Mucinous Neoplasms of the Pancreas. PANCREAS, 44(8), 1402. Retrieved from https://www.webofscience.com/
Cathepsin D Expression in Pancreatic Ductal Adenocarcinoma (PDAC) Cells Increases Proliferation and Reduces Survival of Pancreatic Cancer Patients
Mahajan, U. M., Langhoff, E., Costello, E., Greenhalf, W., Halloran, C., Schwaiger, T., . . . Mayerle, J. (2015). Cathepsin D Expression in Pancreatic Ductal Adenocarcinoma (PDAC) Cells Increases Proliferation and Reduces Survival of Pancreatic Cancer Patients. In GASTROENTEROLOGY Vol. 148 (pp. S13). Retrieved from https://www.webofscience.com/
Clinical and Biological Features of Patients of Acute Pancreatitis With Transient Organ Failure or Acute Peripancreatic Fluid Collection
Huang, W., Iglesia-Garcia, D., Szatmary, P., Fleming-Bird, L., Altaf, K., Nunes, Q., . . . Sutton, R. (2015). Clinical and Biological Features of Patients of Acute Pancreatitis With Transient Organ Failure or Acute Peripancreatic Fluid Collection. PANCREAS, 44(8), 1379-1380. Retrieved from https://www.webofscience.com/
Cumulative Acute Pancreatitis Outcome Score for Clinical Trials in Acute Pancreatitis
Huang, W., Szatmary, P., Iglesia-Garcia, D., Sud, A., Lane, B., Nunes, Q., . . . Sutton, R. (2015). Cumulative Acute Pancreatitis Outcome Score for Clinical Trials in Acute Pancreatitis. PANCREAS, 44(8), 1380. Retrieved from https://www.webofscience.com/
Cytidine Deaminase (CDA) Transcript Analysis Complements hENT1 Protein Staining in Predicting Gemcitabine Response in the ESPAC-3 Pancreatic Cancer Cohort
Elander, N., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Costello, E., Palmer, D., . . . Greenhalf, W. (2015). Cytidine Deaminase (CDA) Transcript Analysis Complements hENT1 Protein Staining in Predicting Gemcitabine Response in the ESPAC-3 Pancreatic Cancer Cohort. PANCREAS, 44(8), 1371. Retrieved from https://www.webofscience.com/
Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Cancer or Diabetes Development?
Jenkinson, C., Elliott, V. L., Evans, A., Oldfield, L., Timms, J. F., Gentry-Maharaj, A., . . . Costello, E. (2015). Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Cancer or Diabetes Development?. In PANCREAS Vol. 44 (pp. 1383). Retrieved from https://www.webofscience.com/
Early Prediction of Major Clinical Outcomes of Patients With Acute Pancreatitis by Circulating Histones
Liu, T., Huang, W., Szatmary, P., Abrams, S. T., Greenhalf, W., Welters, I., . . . Toh, C. H. (2015). Early Prediction of Major Clinical Outcomes of Patients With Acute Pancreatitis by Circulating Histones. PANCREAS, 44(8), 1393. Retrieved from https://www.webofscience.com/
Early Prediction of Persistent Organ Failure in Patients With Acute Pancreatitis
Huang, W., Szatmary, P., Iglesia-Garcia, D., Fleming-Bird, L., Parente, S., Primo, G., . . . Sutton, R. (2015). Early Prediction of Persistent Organ Failure in Patients With Acute Pancreatitis. PANCREAS, 44(8), 1380. Retrieved from https://www.webofscience.com/
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.
Nicholson, J., Greenhalf, B., Jackson, R., Cox, T., Butler, J., Hanna, T., . . . Neoptolemos, J. (2015). Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.. Pancreas, 44(02), 260-265. doi:10.1097/MPA.0000000000000246
Inhibition of Hedgehog Pathway in 2D and 3D Co-cultures of CAFs and PDAC Cell Lines
Brumskill, S., Barrera, L., Campbell, F., Halloran, C., Greenhalf, W., Ghirelli, C., . . . Costello, E. (2015). Inhibition of Hedgehog Pathway in 2D and 3D Co-cultures of CAFs and PDAC Cell Lines. PANCREAS, 44(8), 1363-1364. Retrieved from https://www.webofscience.com/
Pancreatic Human Fibroblast Expression Profiling Reveals Novel microRNAs and mRNAs in the Diseased Pancreas
Barrera, L., Lane, B., Brumskill, S., Oldfield, F., Nunes, Q., Campbell, F., . . . Costello, E. (2015). Pancreatic Human Fibroblast Expression Profiling Reveals Novel microRNAs and mRNAs in the Diseased Pancreas. PANCREAS, 44(8), 1361-1362. Retrieved from https://www.webofscience.com/
Pancreatic Mass in a Young <i>CFTR</i> Carrier With a Heterozygous p.R117H <i>CFTR</i> Gene Mutation and Homozygous 7T
Hanna, T., Abdul-Rahman, Z., Greenhalf, W., Costello, E., & Neoptolemos, J. P. (2015). Pancreatic Mass in a Young <i>CFTR</i> Carrier With a Heterozygous p.R117H <i>CFTR</i> Gene Mutation and Homozygous 7T. PANCREAS, 44(2), 343-345. doi:10.1097/MPA.0000000000000244
Pattern and Impact of Organ Failure on Human Acute Pancreatitis
Szatmary, P., Huang, W., Liu, T., de la Iglesia-Garcia, D., Parente, S., Primo, G., . . . Sutton, R. (2015). Pattern and Impact of Organ Failure on Human Acute Pancreatitis. PANCREAS, 44(8), 1418. Retrieved from https://www.webofscience.com/
Pattern of Infective Complications in Human Acute Pancreatitis
Szatmary, P., Huang, W., de la Iglesia-Garcia, D., Parente, S., Primo, G., Greenhalf, W., & Sutton, R. (2015). Pattern of Infective Complications in Human Acute Pancreatitis. PANCREAS, 44(8), 1418. Retrieved from https://www.webofscience.com/
Potential Biomarkers of Pancreatic Ductal Adenocarcinoma-Associated Diabetes
Oldfield, L., Jenkinson, C., Purewal, T., Sutton, R., Neoptolemos, J. P., Greenhalf, W., & Costello, E. (2015). Potential Biomarkers of Pancreatic Ductal Adenocarcinoma-Associated Diabetes. PANCREAS, 44(8), 1404-1405. Retrieved from https://www.webofscience.com/
2014
Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca2+-dependent mitochondrial dysfunction and acute pancreatitis
Huang, W., Booth, D., Cane, M. C., Chvanov, M., Javed, M. A., Elliott, V., . . . Criddle, D. (2014). Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca2+-dependent mitochondrial dysfunction and acute pancreatitis. Gut, 63(8), 1313-1324. doi:10.1136/gutjnl-2012-304058
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Middleton, G., Silcocks, P., Cox, T. F., Valle, J., Wadsley, J., Propper, D., . . . Neoptolemos, J. P. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology, 15(8), 829-840. doi:10.1016/S1470-2045(14)70236-0
Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial
Neoptolemos, J. P., Greenhalf, W., Cox, T. F., Costello, E., Shaw, V., Valle, J. W., . . . Middleton, G. (2014). Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 4121). doi:10.1200/jco.2014.32.15_suppl.4121
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.. Molecular cancer, 13, 114. doi:10.1186/1476-4598-13-114
Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease
Shaw, V. E., Lane, B., Jenkinson, C., Cox, T. F., Greenhalf, W., Halloran, C. M., . . . Costello, E. (2014). Serum cytokine biomarker panels for discriminating Pancreatic Cancer from Benign Pancreatic Disease. Molecular Cancer, 13. Retrieved from https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-114
Combination Therapy With Gemcitabine and a Novel Plk1 Inhibitor Causes Caspase-Independent Cell Death in Pancreatic Cancer Cells
Jones, O. P., Greenhalf, W., Halloran, C., Neoptolemos, J. P., & Ghaneh, P. (2014). Combination Therapy With Gemcitabine and a Novel Plk1 Inhibitor Causes Caspase-Independent Cell Death in Pancreatic Cancer Cells. PANCREAS, 43(8), 1372. Retrieved from https://www.webofscience.com/
Dissecting the Role of Hedgehog Signalling in the Interaction Between Pancreatic Stellate Cells and Pancreatic Tumour Cells Using 2D and 3D Modelling
Brumskill, S., Barrera, L., Campbell, F., Halloran, C., Greenhalf, W., Campbell, M. -A., & Costello, E. (2014). Dissecting the Role of Hedgehog Signalling in the Interaction Between Pancreatic Stellate Cells and Pancreatic Tumour Cells Using 2D and 3D Modelling. PANCREAS, 43(8), 1346. Retrieved from https://www.webofscience.com/
Keeping on top of data samples with LIMS
Greenhalf, W., & Boother, J. (2014). Keeping on top of data samples with LIMS. Manufacturing Chemist, 85(7-8).
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., . . . Büchler, M. W. (2014). Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.. Journal of the National Cancer Institute, 106(1). doi:10.1093/jnci/djt347
Risk of Other Cancers in Familial Pancreatic Cancer
Hanna, T., Nicholson, J., Harrison, S., Johnstone, M., Ghaneh, P., Sutton, R., . . . Greenhalf, W. (2014). Risk of Other Cancers in Familial Pancreatic Cancer. PANCREAS, 43(8), 1363. Retrieved from https://www.webofscience.com/
The Diagnosis of Chronic Pancreatitis: A Systematic Review and Meta-analysis
Johnstone, M., Jackson, R., Hanna, T., Nicholson, J., Neoptolemos, J. P., Greenhalf, W., & Sutton, R. (2014). The Diagnosis of Chronic Pancreatitis: A Systematic Review and Meta-analysis. PANCREAS, 43(8), 1372. Retrieved from https://www.webofscience.com/
2013
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
Tonack, S., Jenkinson, C., Cox, T., Elliott, V., Jenkins, R. E., Kitteringham, N. R., . . . Costello, E. (2013). iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. BRITISH JOURNAL OF CANCER, 108(9), 1846-1853. doi:10.1038/bjc.2013.150
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., . . . Kumar, R. (2013). Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival. PLOS ONE, 8(4). doi:10.1371/journal.pone.0060870
ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.
Rizzato, C., Campa, D., Pezzilli, R., Soucek, P., Greenhalf, W., Capurso, G., . . . Canzian, F. (2013). ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.. Oncology reports, 29(4), 1637-1644. doi:10.3892/or.2013.2285
A multistate modelling approach for pancreatic cancer development in genetically high-risk families
Kolamunnage-Dona, R., Vitone, L., Greenhalf, W., Henderson, R., & Williamson, P. R. (2013). A multistate modelling approach for pancreatic cancer development in genetically high-risk families. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 62(2), 201-212. doi:10.1111/j.1467-9876.2012.01051.x
Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
Campa, D., Rizzato, C., Capurso, G., Giese, N., Funel, N., Greenhalf, W., . . . Canzian, F. (2013). Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 45(2), 95-99. doi:10.1016/j.dld.2012.09.014
Fatty Acid Ethyl Ester Synthase Inhibition Ameliorates Ethanol-Induced Ca<SUP>2+</SUP>-Dependent Mitochondrial Dysfunction and Acute Pancreatitis
Huang, W., Booth, D. M., Cane, M. C., Chvanov, M., Javed, M. A., Elliot, V. L., . . . Criddle, D. N. (2013). Fatty Acid Ethyl Ester Synthase Inhibition Ameliorates Ethanol-Induced Ca<SUP>2+</SUP>-Dependent Mitochondrial Dysfunction and Acute Pancreatitis. PANCREAS, 42(8), 1355. Retrieved from https://www.webofscience.com/
Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
Campa, D., Rizzato, C., Capurso, G., Giese, N., Funel, N., Greenhalf, W., . . . Canzian, F. (2013). Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. DIGESTIVE AND LIVER DISEASE, 45(2), 95-99. doi:10.1016/j.dld.2012.09.014
Isolation of Quiescent and Activated Human Pancreatic Stellate Cells for MicroRNA Profiling
Barrera, L., Oldfield, F., Nunes, Q., Campbell, F., Lane, B., Andrews, T., . . . Costello, E. (2013). Isolation of Quiescent and Activated Human Pancreatic Stellate Cells for MicroRNA Profiling. PANCREAS, 42(8), 1339. Retrieved from https://www.webofscience.com/
Micro RNA Profiling in Acute Pancreatitis
Altaf, K., Lane, B., Rainbow, L., Halloran, C., Greenhalf, W., & Sutton, R. (2013). Micro RNA Profiling in Acute Pancreatitis. In PANCREAS Vol. 42 (pp. 1337). Retrieved from https://www.webofscience.com/
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., . . . Kumar, R. (n.d.). Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival. PLoS ONE, 8(4), e60870. doi:10.1371/journal.pone.0060870
hENT1 Tumor Expression Predicts Longer Survival in Patients with Resection for Pancreatic Ductal Adenocarcinoma Randomized to Adjuvant Gemcitabine in the ESPAC Trials
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Garner, E., . . . he European Study Group for Pancreatic Cancer, F. (2013). hENT1 Tumor Expression Predicts Longer Survival in Patients with Resection for Pancreatic Ductal Adenocarcinoma Randomized to Adjuvant Gemcitabine in the ESPAC Trials. JNCI, Accept.
2012
Common genetic variants in the <i>CLDN2</i> and <i>PRSS1-PRSS2</i> loci alter risk for alcohol-related and sporadic pancreatitis
Whitcomb, D. C., LaRusch, J., Krasinskas, A. M., Klei, L., Smith, J. P., Brand, R. E., . . . Yu, L. (2012). Common genetic variants in the <i>CLDN2</i> and <i>PRSS1-PRSS2</i> loci alter risk for alcohol-related and sporadic pancreatitis. NATURE GENETICS, 44(12), 1349-1354. doi:10.1038/ng.2466
Divisum may be preserving pancreatic function in CFTR patients-but at a cost.
Nicholson, J. A., Johnstone, M., & Greenhalf, W. (2012). Divisum may be preserving pancreatic function in CFTR patients-but at a cost.. The American journal of gastroenterology, 107(11), 1758-1759. doi:10.1038/ajg.2012.302
New biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012). New biomarkers and targets in pancreatic cancer and their application to treatment. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 9(8), 435-444. doi:10.1038/nrgastro.2012.119
A multistate modelling approach for pancreatic cancer development in genetically high risk families
Kolamunnage-Dona, R., Vitone, L., Greenhalf, W., Henderson, R., & Williamson, P. R. (2012). A multistate modelling approach for pancreatic cancer development in genetically high risk families. Journal of the Royal Statistical Society: Series C (Applied Statistics). Retrieved from http://dx.doi.org/10.1111/j.1467-9876.2012.01051.x
Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue
Bauer, A. S., Keller, A., Costello, E., Greenhalf, W., Bier, M., Borries, A., . . . Hoheisel, J. D. (2012). Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue. PLOS ONE, 7(4). doi:10.1371/journal.pone.0034151
2011
Pancreatic Cancer Susceptibility Loci and Their Role in Survival
Rizzato, C., Campa, D., Giese, N., Werner, J., Rachakonda, P. S., Kumar, R., . . . Canzian, F. (2011). Pancreatic Cancer Susceptibility Loci and Their Role in Survival. PLOS ONE, 6(11). doi:10.1371/journal.pone.0027921
Combination therapy for the treatment of pancreatic cancer.
Greenhalf, W., & Thomas, A. (2011). Combination therapy for the treatment of pancreatic cancer.. Anti-cancer agents in medicinal chemistry, 11(5), 418-426. doi:10.2174/187152011795677391
2010
Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer
Tweedle, E. M., Khattak, I., Ang, C. W., Nedjadi, T., Jenkins, R., Park, B. K., . . . Costello, E. (2010). Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. GUT, 59(11), 1501-1510. doi:10.1136/gut.2009.196626
PALB2 mutations in European familial pancreatic cancer families.
Slater, E. P., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., . . . Bartsch, D. K. (2010). PALB2 mutations in European familial pancreatic cancer families.. Clinical genetics, 78(5), 490-494. doi:10.1111/j.1399-0004.2010.01425.x
Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer
Shaw, V. E., Naisbitt, D. J., Costello, E., Greenhalf, W., Park, B. K., Neoptolemos, J. P., & Middleton, G. W. (2010). Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. EXPERT REVIEW OF VACCINES, 9(9), 1007-1016. doi:10.1586/ERV.10.92
CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer.
Ripka, S., Neesse, A., Riedel, J., Bug, E., Aigner, A., Poulsom, R., . . . Michl, P. (2010). CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer.. Gut, 59(8), 1101-1110. doi:10.1136/gut.2009.189720
The variable phenotype of the p.A16V mutation of cationic trypsinogen (<i>PRSS1</i>) in pancreatitis families
Grocock, C. J., Rebours, V., Delhaye, M. N., Andren-Sandberg, A., Weiss, F. U., Mountford, R., . . . Greenhalf, W. (2010). The variable phenotype of the p.A16V mutation of cationic trypsinogen (<i>PRSS1</i>) in pancreatitis families. GUT, 59(3), 357-363. doi:10.1136/gut.2009.186817
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Dive, C., Smith, R. A., Garner, E., Ward, T., George-Smith, S. S., Campbell, F., . . . Neoptolemos, J. P. (2010). Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.. British journal of cancer, 102(3), 577-582. doi:10.1038/sj.bjc.6605494
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
Dive, C., Smith, R. A., Garner, E., Ward, T., George-Smith, S. S., Campbell, F., . . . Neoptolemos, J. P. (2010). Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. British Journal of Cancer, 102(3), 577-582. doi:10.1038/sj.bjc.6605494
Genetic Susceptibility
Greenhalf, W., & Neoptolemos, J. (2010). Genetic Susceptibility. In J. L. Abbruzzese, M. W. Buchler, R. Urrutia, & J. Neoptolemos (Eds.), Handbook of Pancreatic Cancer (Vol. In Pre). New York: Springer-Verlag.
Inherited genetics of pancreatic cancer and secondary screening
Greenhalf, W., & Neoptolemos, J. (2010). Inherited genetics of pancreatic cancer and secondary screening. In J. L. Abbruzzese, M. W. Buchler, R. Urrutia, & J. Neoptolemos (Eds.), Handbook of Pancreatic Cancer (Vol. In Pri). New York: Springer-Verlag.
Single-nucleotide polymorphism (SNP) analysis to associate cancer risk.
Earl, J., & Greenhalf, W. (2010). Single-nucleotide polymorphism (SNP) analysis to associate cancer risk.. Methods in molecular biology (Clifton, N.J.), 576, 171-196. doi:10.1007/978-1-59745-545-9_10
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families.
Grocock, C. J., Rebours, V., Delhaye, M. N., Andrén-Sandberg, A., Weiss, F. U., Mountford, R., . . . European Registry of Hereditary Pancreatitis Pancreatic Cancer. (2010). The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families.. Gut, 59(3), 357-363.
2009
Medical Treatment of Chronic Pancreatitis
Mössner, J., Layer, P., Keller, J., Mullady, D. K., O'Keefe, S. J. D., Howes, N., . . . Raraty, M. G. T. (2009). Medical Treatment of Chronic Pancreatitis. In The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery: Second Edition (pp. 504-526). doi:10.1002/9781444300123.ch52
Factors involved in carcinogenesis and prevention in hepatobiliary cancer
Ghaneh, P., Greenhalf, W., & Neoptolemos, J. P. (2009). Factors involved in carcinogenesis and prevention in hepatobiliary cancer. In Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach (pp. 421-432).
Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer
Yan, L., Tonack, S., Smith, R., Dodd, S., Jenkins, R. E., Kitteringham, N., . . . Costello, E. (2009). Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer. JOURNAL OF PROTEOME RESEARCH, 8(1), 142-148. doi:10.1021/pr800451h
Screening of high-risk families for pancreatic cancer.
Greenhalf, W., Grocock, C., Harcus, M., & Neoptolemos, J. (2009). Screening of high-risk families for pancreatic cancer.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 9(3), 215-222. doi:10.1159/000210262
The inherited genetic component of sporadic pancreatic adenocarcinoma.
Milne, R. L., Greenhalf, W., Murta-Nascimento, C., Real, F. X., & Malats, N. (2009). The inherited genetic component of sporadic pancreatic adenocarcinoma.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 9(3), 206-214. doi:10.1159/000210261
2008
New treatment options for advanced pancreatic cancer.
Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2008). New treatment options for advanced pancreatic cancer.. Expert review of gastroenterology & hepatology, 2(5), 673-696. doi:10.1586/17474124.2.5.673
Familial Pancreatic Cancer
Greenhalf, W., Vitone, L. J., & Neoptolemos, J. P. (2008). Familial Pancreatic Cancer. In Unknown Book (pp. 591-600). Wiley. doi:10.1002/9781444300123.ch59
Medical Treatment of Chronic Pancreatitis
Mössner, J., Layer, P., Keller, J., Mullady, D. K., Oí'Keefe, S. J. D., Howes, N., . . . Raraty, M. G. T. (2008). Medical Treatment of Chronic Pancreatitis. In Unknown Book (pp. 504-526). Wiley. doi:10.1002/9781444300123.ch52
Screening of Hereditary Pancreatic Cancer Families
Carlson, C., Greenhalf, W., & Brentnall, T. A. (2008). Screening of Hereditary Pancreatic Cancer Families. In Unknown Book (pp. 636-642). Wiley. doi:10.1002/9781444300123.ch64
International registries of families at high risk of pancreatic cancer.
Greenhalf, W., Malats, N., Nilsson, M., Bartsch, D., & Neoptolemos, J. (2008). International registries of families at high risk of pancreatic cancer.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 8(6), 558-565. doi:10.1159/000159214
2007
Familial pancreatic cancer: a review and latest advances.
Grocock, C. J., Vitone, L. J., Harcus, M. J., Neoptolemos, J. P., Raraty, M. G. T., & Greenhalf, W. (2007). Familial pancreatic cancer: a review and latest advances.. Advances in medical sciences, 52, 37-49.
Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition
Burkitt, M., Magee, C., O'Connor, D., Campbell, F., Cornford, P., & Greenhalf, W. (2007). Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. MOLECULAR CARCINOGENESIS, 46(6), 466-475. doi:10.1002/mc.20296
Palladin mutation causes familial pancreatic cancer: absence in European families.
Slater, E., Amrillaeva, V., Fendrich, V., Bartsch, D., Earl, J., Vitone, L. J., . . . Greenhalf, W. (2007). Palladin mutation causes familial pancreatic cancer: absence in European families.. PLoS medicine, 4(4), e164. doi:10.1371/journal.pmed.0040164
Absence of the palladin P239S mutation in European pancreatic cancer families.
Slater, E. P., Amrillaeva, V., Fendrich, V., Bartsch, D. K., for., FaPaCa., . . . Europac. (2007). Absence of the palladin P239S mutation in European pancreatic cancer families.. PLoS Medicine, 4(4), e164. Retrieved from http://medicine.plosjournals.org/
Diabetes is a Risk Factor for Pancreatic Cancer.
Vitone, L. J., Charnley, R., Simon, P., Dodd, S., Grocock, C., Delhaye, M., . . . on, O. B. O. T. E. R. O. H. P. (2007). Diabetes is a Risk Factor for Pancreatic Cancer.. Pancreatology, 7, 221.
Familial Pancreatic Cancer.
Greenhalf, W., Vitone, L. J., & Neoptolemos, J. P. (2007). Familial Pancreatic Cancer.. In H. Beger, M. Buchler, R. Kozarek, M. Lerch, J. P. Neoptolemos, A. Warshaw, . . . H. Beger (Eds.), The Pancreas : A Clinical and Surgical Text (pp. Section 5, Chapter 60). Ulm: Blackwell Publishing.
Familial Pancreatic Cancer: a review and latest advances.
Grocock, C., Vitone, L. J., Harcus, M. J., Neoptolemos, J. P., Raraty, M. G., & Greenhalf, W. (2007). Familial Pancreatic Cancer: a review and latest advances.. Advances in Medical Sciences, 52, 37-49.
Familial pancreatic cancer: a review and latest advances
Grocock, C. J., Vitone, L. J., Harcus, M. J., Neoptolemos, J. P., Raraty, M. G., & Greenhalf, W. (2007). Familial pancreatic cancer: a review and latest advances. Adv Med Sci, 52, 37-49. Retrieved from http://www.ncbi.nlm.nih.gov/
Palladin mutation causes familial pancreatic cancer: absence in European families
Slater, E., Amrillaeva, V., Fendrich, V., Bartsch, D., Earl, J., Vitone, L. J., . . . Greenhalf, W. (2007). Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med, 4(4), e164.
The Association of the Palladin P239S Mutation and European Familial Pancreatic Cancer Families.
Earl, J., Slater, E. P., Yan, L., Vitone, L. J., Grocock, C., Harcus, M., . . . Greenhalf, W. (2007). The Association of the Palladin P239S Mutation and European Familial Pancreatic Cancer Families.. Pancreatology, 7, 278.
2006
Peutz-Jeghers syndrome and screening for pancreatic cancer.
Latchford, A., Greenhalf, W., Vitone, L. J., Neoptolemos, J. P., Lancaster, G. A., & Phillips, R. K. S. (2006). Peutz-Jeghers syndrome and screening for pancreatic cancer.. The British journal of surgery, 93(12), 1446-1455. doi:10.1002/bjs.5609
An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.
Greenhalf, W. (2006). An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.. Gut, 55(11), 1533-1535. doi:10.1136/gut.2006.098814
Evaluation of the <i>4q32-34</i> locus in European familial pancreatic
Earl, J., Yan, L., Vitone, L. J., Risk, J., Kemp, S. J., McFaul, C., . . . Bartsch, D. K. (2006). Evaluation of the <i>4q32-34</i> locus in European familial pancreatic. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 15(10), 1948-1955. doi:10.1158/1055-9965.EPI-06-0376
Increasing survival rates of patients with pancreatic cancer by earlier identification.
Greenhalf, W., & Neoptolemos, J. P. (2006). Increasing survival rates of patients with pancreatic cancer by earlier identification.. Nature clinical practice. Oncology, 3(7), 346-347. doi:10.1038/ncponc0483
Trypsinogen mutations in pancreatic disorders.
Vitone, L. J., Greenhalf, W., Howes, N. R., Raraty, M. G. T., & Neoptolemos, J. P. (2006). Trypsinogen mutations in pancreatic disorders.. Endocrinology and metabolism clinics of North America, 35(2), 271-viii. doi:10.1016/j.ecl.2006.02.006
The inherited genetics of pancreatic cancer and prospects for secondary screening.
Vitone, L. J., Greenhalf, W., McFaul, C. D., Ghaneh, P., & Neoptolemos, J. P. (2006). The inherited genetics of pancreatic cancer and prospects for secondary screening.. Best practice & research. Clinical gastroenterology, 20(2), 253-283. doi:10.1016/j.bpg.2005.10.007
Anticipation in familial pancreatic cancer.
McFaul, C. D., Greenhalf, W., Earl, J., Howes, N., Neoptolemos, J. P., Kress, R., . . . German National Case Collection for Familial Pancreatic Cancer (FaPaCa). (2006). Anticipation in familial pancreatic cancer.. Gut, 55(2), 252-258. doi:10.1136/gut.2005.065045
Diabetes Mellitus and Pancreatic Cancer risk in HP (Hereditary Pancreatitis)
Vitone, L., Howes, N., Mountford, R., Murali-Krishnan, G., Neoptolemos, J. P., & Greenhalf, W. (2006). Diabetes Mellitus and Pancreatic Cancer risk in HP (Hereditary Pancreatitis). Pancreatology, 6, 196.
Temporal and serum dependence of potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin
Magee, C. J., Burkitt, M., O'Connor, D. I., Campbell, F., Cornford, P., & Greenhalf, N. A. (2006). Temporal and serum dependence of potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin. Molecular Carcinogenesis.
2005
<i>RNASEL</i> germline variants are associated with pancreatic cancer
Bartsch, D. K., Fendrich, V., Slater, E. P., Sina‐Frey, M., Rieder, H., Greenhalf, W., . . . Kress, R. (2005). <i>RNASEL</i> germline variants are associated with pancreatic cancer. International Journal of Cancer, 117(5), 718-722. doi:10.1002/ijc.21254
RNASEL germline variants are associated with pancreatic cancer.
Bartsch, D. K., Fendrich, V., Slater, E. P., Sina-Frey, M., Rieder, H., Greenhalf, W., . . . Kress, R. (2005). RNASEL germline variants are associated with pancreatic cancer.. International journal of cancer, 117(5), 718-722. doi:10.1002/ijc.21254
Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers.
Cohn, J. A., Neoptolemos, J. P., Feng, J., Yan, J., Jiang, Z., Greenhalf, W., . . . Sommer, S. S. (2005). Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers.. Human mutation, 26(4), 303-307. doi:10.1002/humu.20232
High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients
Vimalachandran, D., Greenhalf, W., Thompson, C., Lüttges, J., Prime, W., Campbell, F., . . . Costello, E. (2005). High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. CANCER RESEARCH, 65(8), 3218-3225. doi:10.1158/0008-5472.CAN-04-4311
Cationic trypsinogen mutations and pancreatitis.
Howes, N., Greenhalf, W., Stocken, D. D., & Neoptolemos, J. P. (2005). Cationic trypsinogen mutations and pancreatitis.. Clinics in laboratory medicine, 25(1), 39-59. doi:10.1016/j.cll.2004.12.004
Exclusion Mapping of the 4q32-34 Locus in 41 European FPC Families
Earl, J., Kress, R., Yan, L., Howes, N., Leslie, J., Vitone, L., . . . Greenhalf, W. (2005). Exclusion Mapping of the 4q32-34 Locus in 41 European FPC Families. Pancreatology, 5(Suppl), 106.
Familial pancreatic cancer syndromes
Hahn, S., Vitone, L., Greenhalf, W., Bartsch, D., & Neoptolemos, J. P. (2005). Familial pancreatic cancer syndromes. In T. M. Gress, J. P. Neoptoelmos, N. R. Lemoine, & F. X. Real (Eds.), Exocrine pancreas cancer (pp. 44-61). Hannover: Felsenstein CCCP.
Functional Analysis of S100A6 (Calcyclin) in Pancreatic Cancer Patients
Nedjadi, T., Vimalachandran, D., Thompson, C. C. M., Lüttges, J., Prime, W., Campbell, F., . . . Costello, E. (2005). Functional Analysis of S100A6 (Calcyclin) in Pancreatic Cancer Patients. Pancreatology, 5(Suppl), 45.
Hereditary pancreatitis and secondary screening for early pancreatic cancer.
Vitone, L. J., Greenhalf, W., Howes, N. R., & Neoptolemos, J. P. (2005). Hereditary pancreatitis and secondary screening for early pancreatic cancer.. Roczniki Akademii Medycznej w Bialymstoku (1995), 50, 73-84.
Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups.
Yan, L., McFaul, C., Howes, N., Leslie, J., Lancaster, G., Wong, T., . . . Greenhalf, W. (2005). Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups.. Gastroenterology, 128(7), 2124-2130. doi:10.1053/j.gastro.2005.03.006
Molecular diagnosis of pancreatic cancer in pancreatic juice
Greenhalf, W., Vitone, L., & Neoptolemos, J. P. (2005). Molecular diagnosis of pancreatic cancer in pancreatic juice. In T. M. Gress, J. P. Neoptolemos, N. R. Lemoine, & F. X. Real (Eds.), Exocrine pancreas cancer (pp. 404-425). Hannover: Felenstein CCCP.
Promoter Methylation Detected in Pancreatic Juice: Relationship with Cancer, Age and Survival
Yan, L., Vitone, L., Earl, J., Howes, N., Leslie, J., Lancaster, G., . . . Greenhalf, W. (2005). Promoter Methylation Detected in Pancreatic Juice: Relationship with Cancer, Age and Survival. Pancreatology, 5(Suppl), 89.
Secondary screening for pancreatic cancer in high risk groups
Vitone, L., Greenhalf, W., & Neoptolemos, J. P. (2005). Secondary screening for pancreatic cancer in high risk groups. In T. M. Gress, J. P. Neoptolemos, N. R. Lemoine, & F. X. Real (Eds.), Exocrine pancreas cancer (pp. 310-329). Hannover: Felenstein CCCP.
The Founder Effect in N29I Mutations is Greater than in R122H Mutations of the Cationic Trypsinogen Gene
Vitone, L., Greenhalf, W., Howes, N., Wong, T., Mountford, R., Blake, V., & Neoptolemos, J. P. (2005). The Founder Effect in N29I Mutations is Greater than in R122H Mutations of the Cationic Trypsinogen Gene. Pancreatology, 5(Suppl), 109.
2004
Cationic trypsinogen mutations and pancreatitis.
Howes, N., Greenhalf, W., Stocken, D. D., & Neoptolemos, J. P. (2004). Cationic trypsinogen mutations and pancreatitis.. Gastroenterology clinics of North America, 33(4), 767-787. doi:10.1016/j.gtc.2004.07.003
Screening Method
Greenhalf, W., & O'Connor, D. I. (2004). Screening Method.
No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.
Grützmann, R., McFaul, C., Bartsch, D. K., Sina-Frey, M., Rieder, H., Koch, R., . . . Pilarsky, C. (2004). No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.. Cancer letters, 214(1), 63-68. doi:10.1016/j.canlet.2004.06.012
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells
Halloran, C. M., Ghaneh, P., Shore, S., Greenhalf, W., Zumstein, L., Wilson, D., . . . Costello, E. (2004). 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16<SUP>INK4A</SUP> greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. JOURNAL OF GENE MEDICINE, 6(5), 514-525. doi:10.1002/jgm.540
Clinical and genetic characteristics of hereditary pancreatitis in Europe.
Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., . . . European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). (2004). Clinical and genetic characteristics of hereditary pancreatitis in Europe.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2(3), 252-261. doi:10.1016/s1542-3565(04)00013-8
Detection of p53 Mutations in Pancreatic Cancer and Chronic Pancreatitis
McFaul, C. D., Yan, L., Howes, N., Wong, T., Leslie, J. A., Threadgold, J., . . . Neoptolemos, J. P. (2004). Detection of p53 Mutations in Pancreatic Cancer and Chronic Pancreatitis. Pancreatology, 4(2), 144.
FPC Families Unlinked to the 4q32-34 Locus
Earl, J., Yan, L., Kress, R., Leslie, J., McFaul, C. D., Rieder, H., . . . Neoptolemos, J. P. (2004). FPC Families Unlinked to the 4q32-34 Locus. Pancreatology, 4(2), 146.
Genetic anticipation in familial pancreatic cancer
McFaul, C. D., Kress, R., Bartsch, D. K., Rieder, H., Sina-Frey, M., Neoptolemos, J. P., & Greenhalf, W. (2004). Genetic anticipation in familial pancreatic cancer. British Journal Of Cancer, 91, S40.
Identification of a familial pancreatic cancer gene by focusing haplotype analysis using LOH in sporadic cancer
Leslie, J., McFaul, C., Earl, J., Azadeh, B., Prime, W., Bartsch, D., . . . Greenhalf, W. (2004). Identification of a familial pancreatic cancer gene by focusing haplotype analysis using LOH in sporadic cancer. British Journal Of Cancer, 91, S31.
LOH Analysis in Sporadic Pancreatic Cancer to Identify Novel Familial Pancreatic Cancer Genes
Leslie, J. A., Earl, J., McFaul, C. D., Azadeh, B., Prime, W., Sibson, R., . . . Greenhalf, W. (2004). LOH Analysis in Sporadic Pancreatic Cancer to Identify Novel Familial Pancreatic Cancer Genes. Pancreatology, 4(2), 149.
P53 mutations in patients with pancreatic cancer and chronic pancreatitis
Yan, L., McFaul, C., Malats, N., Threadgold, J., Howes, N., Leslie, J., . . . Greenhalf, W. (2004). P53 mutations in patients with pancreatic cancer and chronic pancreatitis. British Journal Of Cancer, 91, S31.
2003
BRCA2 germline mutations in familial pancreatic carcinoma.
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., . . . Bartsch, D. K. (2003). BRCA2 germline mutations in familial pancreatic carcinoma.. Journal of the National Cancer Institute, 95(3), 214-221. doi:10.1093/jnci/95.3.214
BRCA2 germline mutations in familial pancreatic carcinoma
BRCA2 germline mutations in familial pancreatic carcinoma (2003). Gastroenterology, 124(4), A548.
BRCA2 germline mutations in familial pancreatic carcinoma
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Gerdes, B., . . . Bartsch, D. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. Gastroenterology, 124(4), A548.
Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas
Evans, J. D., Cornford, P. A., Dodson, A., Greenhalf, W., Foster, C. S., & Neoptolemos, J. P. (2003). Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology, 1(3), 254-262. Retrieved from http://www.ncbi.nlm.nih.gov/
Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers
Yan, J., Cohn, J., Neoptolemos, J., Feng, J., Jiang, Z., Greenhalf, W., . . . Sommer, S. (2003). Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. American Journal of Human Genetics, 73(5), 1252.
Nuclear Sequestration of Hsp90 Sensitises Pancreatic Cancer (PC) Cells to Apoptosis that Can also Be Induced by Hsp90 Inhibition
Magee, C. J., Burkitt,, M., Evans,, J., Cornford, P., Spiller, D., White, M., . . . Greenhalf, W. (2003). Nuclear Sequestration of Hsp90 Sensitises Pancreatic Cancer (PC) Cells to Apoptosis that Can also Be Induced by Hsp90 Inhibition. Pancreatology, 3, 78.
Nuclear sequestration of Hsp90 sensitises pancreatic cancer (PC) cells to apoptosis that can also be induced by Hsp90 inhibition and alters the balance of Apaf-1 isoforms to pro-apoptotic forms
Magee, C. J., Burkitt, M., Evans, J., Cornford, P., Spiller, D., White, M., . . . Greenhalf, W. (2003). Nuclear sequestration of Hsp90 sensitises pancreatic cancer (PC) cells to apoptosis that can also be induced by Hsp90 inhibition and alters the balance of Apaf-1 isoforms to pro-apoptotic forms. BRITISH JOURNAL OF SURGERY, 90(5), 635. Retrieved from https://www.webofscience.com/
2002
The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease.
Threadgold, J., Greenhalf, W., Ellis, I., Howes, N., Lerch, M. M., Simon, P., . . . Neoptolemos, J. P. (2002). The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease.. Gut, 50(5), 675-681. doi:10.1136/gut.50.5.675
Comprehensive detection of CFTR mutations in idiopathic chronic pancreatitis
Feng, J., Cohn,, J. A., Neoptolemus, J. P., Jiang, Z., Greenhalf, W., Ellis, I., & Somme, S. S. (2002). Comprehensive detection of CFTR mutations in idiopathic chronic pancreatitis. American Journal of Human Genetics, 71(4), 1833.
Hereditary pancreatitis (HP) and the risk of pancreatic ductal adenocarcinoma (PDAC)
Howes, N., Lerch, M. M., Charnley, R., Mossner, J., Endres, S., Deviere, J., . . . Neoptolemos, J. P. (2002). Hereditary pancreatitis (HP) and the risk of pancreatic ductal adenocarcinoma (PDAC). Gut, 50, 155.
2001
Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications.
Magee, C. J., Greenhalf, W., Howes, N., Ghaneh, P., & Neoptolemos, J. P. (2001). Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications.. Surgical oncology, 10(1-2), 1-23. doi:10.1016/s0960-7404(01)00016-0
Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.
Humphreys, M. J., Ghaneh, P., Greenhalf, W., Campbell, F., Clayton, T. M., Everett, P., . . . Neoptolemos, J. P. (2001). Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.. Gene therapy, 8(16), 1241-1247. doi:10.1038/sj.gt.3301518
Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.
Ghaneh, P., Greenhalf, W., Humphreys, M., Wilson, D., Zumstein, L., Lemoine, N. R., & Neoptolemos, J. P. (2001). Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.. Gene therapy, 8(3), 199-208. doi:10.1038/sj.gt.3301394
A new polymorphism for the RI22H mutation in hereditary pancreatitis.
Howes, N., Greenhalf, W., Rutherford, S., O'Donnell, M., Mountford, R., Ellis, I., . . . Neoptolemos, J. P. (2001). A new polymorphism for the RI22H mutation in hereditary pancreatitis.. Gut, 48(2), 247-250. doi:10.1136/gut.48.2.247
Adenovirus-mediated transfer of p53 and p16INK4a results in pancreatic cancer regression in vitro and in vivo
Ghaneh, P., Greenhalf, W., Humphreys, M., Wilson, D., Zumstein, L., Lemoine, N. R., & Neoptolemos, J. P. (2001). Adenovirus-mediated transfer of p53 and p16INK4a results in pancreatic cancer regression in vitro and in vivo. Gene Therapy, 8(3), 199-208. doi:10.1038/sj.gt.3301394
ARMS (TM) detection in real time of under-represented mutant K- ras sequence in patients at risk of pancreatic cancer
Callaghan, K., Howes, N., Greenhalf, W., Neoptolemos, J. P., & Fox, J. C. (2001). ARMS (TM) detection in real time of under-represented mutant K- ras sequence in patients at risk of pancreatic cancer. Pancreatology, 1(5), P217.
Clinical and genetic characteristics of 101 families with hereditary pancreatitis on the EUROPAC Register
Ellis, I., Howes, N., Greenhalf, B., Mountford, R., O'Donnell, M., Lerch, M. M., . . . Neoptolemos, J. P. (2001). Clinical and genetic characteristics of 101 families with hereditary pancreatitis on the EUROPAC Register. Journal Of Medical Genetics, 38, S22.
Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas
Evans, J. D., Cornford, P. A., Dodson, A., Greenhalf, W., Foster, C. S., & Neoptolemos, J. P. (2001). Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. PANCREATOLOGY, 1(3), 254-262. doi:10.1159/000055820
Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients
Wong, T., Howes, N., Threadgold, J., Smart, H. L., Lombard, M. G., Gilmore, I., . . . Neoptolemos, J. P. (2001). Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. PANCREATOLOGY, 1(5), 486-509. doi:10.1159/000055852
Real-time KRAS mutational analysis in the diagnosis of early pancreatic ductal adenocarcinoma
Wong, T., Howes, N., Lombard, M. G., Smart, H. L., Gilmore, I., Sutton, R., . . . Neoptolemos, J. P. (2001). Real-time KRAS mutational analysis in the diagnosis of early pancreatic ductal adenocarcinoma. British Journal of Cancer, 85, 55.
Regulation of expression of S100A4 in pancreatic ductal adenocarcinoma by the zinc finger BKLF
Herbert, C. W., Barraclough, B. R., & Greenhalf, W. (2001). Regulation of expression of S100A4 in pancreatic ductal adenocarcinoma by the zinc finger BKLF. British Journal of Cancer, 85, 55.
Screening pancreatic juice for p53 mutations using a yeast functional assay
Threadgold, J., Howes, N., Ellis, I., Gilmore, I., Smart, H., Lombard, M., . . . Neoptolemos, J. P. (2001). Screening pancreatic juice for p53 mutations using a yeast functional assay. British Journal of Cancer, 85, 54.
TNF-alpha promoter region gene polymorphisms in patients with alcohol-induced chronic pancreatitis
Ahdulrazeg, E. S. M., Alfirevic, A., Gilmore, I. T., Sutton, R., Greenhalf, W., Neoptolemas, J., . . . Pirmohamed, M. (2001). TNF-alpha promoter region gene polymorphisms in patients with alcohol-induced chronic pancreatitis. In Gastroenterology (Vol. 120, Iss. 5, pp. 167). [Paper].
The role of Hsp90 in regulation of apoptosis in pancreatic cancer
Mason, A. B., Burkitt, M., Magee, C. J., O'Connor, D., & Greenhalf, W. (2001). The role of Hsp90 in regulation of apoptosis in pancreatic cancer. British Journal of Cancer, 85, 54.
2000
Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells.
Zhang, H., Cowan-Jacob, S. W., Simonen, M., Greenhalf, W., Heim, J., & Meyhack, B. (2000). Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells.. The Journal of biological chemistry, 275(15), 11092-11099. doi:10.1074/jbc.275.15.11092
Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis.
Howes, N., Greenhalf, W., & Neoptolemos, J. (2000). Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis.. The Medical clinics of North America, 84(3), 719-xii. doi:10.1016/s0025-7125(05)70254-6
1999
A selection system for human apoptosis inhibitors using yeast.
Greenhalf, W., Lee, J., & Chaudhuri, B. (1999). A selection system for human apoptosis inhibitors using yeast.. Yeast (Chichester, England), 15(13), 1307-1321. doi:3.0.co;2-3">10.1002/(sici)1097-0061(19990930)15:13<1307::aid-yea455>3.0.co;2-3
The EUROPAC register of familial pancreatic cancer
Ellis, I., O'Donnell, M., Howes, N., Threadgold, J., Greenhalf, W., Rutherford, S., . . . Neoptolemos, J. (1999). The EUROPAC register of familial pancreatic cancer. Journal of Medical Genetics, 36, S26.
The potential for gene therapy in pancreatic cancer.
Humphreys, M. J., Greenhalf, W., Neoptolemos, J. P., & Ghaneh, P. (1999). The potential for gene therapy in pancreatic cancer.. International journal of pancreatology : official journal of the International Association of Pancreatology, 26(1), 5-21. doi:10.1385/ijgc:26:1:5
1998
Under respiratory growth conditions, Bcl-x(L) and Bcl-2 are unable to overcome yeast cell death triggered by a mutant Bax protein lacking the membrane anchor.
Clow, A., Greenhalf, W., & Chaudhuri, B. (1998). Under respiratory growth conditions, Bcl-x(L) and Bcl-2 are unable to overcome yeast cell death triggered by a mutant Bax protein lacking the membrane anchor.. European journal of biochemistry, 258(1), 19-28. doi:10.1046/j.1432-1327.1998.2580019.x
The p16(INK4A) protein and flavopiridol restore yeast cell growth inhibited by Cdk4.
Moorthamer, M., Panchal, M., Greenhalf, W., & Chaudhuri, B. (1998). The p16(INK4A) protein and flavopiridol restore yeast cell growth inhibited by Cdk4.. Biochemical and biophysical research communications, 250(3), 791-797. doi:10.1006/bbrc.1998.9348
p53 and p16 gene therapy results in killing of pancreatic cancer cells
Ghaneh, P., Humphreys, M., Greenhalf, W., Lemoine, N., & Neoptolemos, J. P. (1998). p53 and p16 gene therapy results in killing of pancreatic cancer cells. British Journal of Surgery, 85(11), 1555.
1996
Efficient flotation of yeast cells grown in batch culture.
Palmieri, M. C., Greenhalf, W., & Laluce, C. (1996). Efficient flotation of yeast cells grown in batch culture.. Biotechnology and bioengineering, 50(3), 248-256. doi:3.0.co;2-g">10.1002/(sici)1097-0290(19960505)50:3<248::aid-bit3>3.0.co;2-g
Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae.
Greenhalf, W., Stephan, C., & Chaudhuri, B. (1996). Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae.. FEBS letters, 380(1-2), 169-175. doi:10.1016/0014-5793(96)00044-0
1995
The maintenance of self-replicating plasmids in Saccharomyces cerevisiae: mathematical modelling, computer simulations and experimental tests.
Van der Sand, S. T., Greenhalf, W., Gardner, D. C., & Oliver, S. G. (1995). The maintenance of self-replicating plasmids in Saccharomyces cerevisiae: mathematical modelling, computer simulations and experimental tests.. Yeast (Chichester, England), 11(7), 641-658. doi:10.1002/yea.320110705
1993
Thermotolerance behavior in sugar cane syrup fermentations of wild type yeast strains selected under pressures of temperature, high sugar and added ethanol
Laluce, C., Abud, C. L., Greenhalf, W., & Sanches, P. M. F. (1993). Thermotolerance behavior in sugar cane syrup fermentations of wild type yeast strains selected under pressures of temperature, high sugar and added ethanol. Biotechnology Letters, 15(6), 609-614. doi:10.1007/bf00138550
1989
A mathematical model for plasmid replication and distribution in microbial populations
Greenhalf, W., Gardner, D. C. J., & Oliver, S. G. (1989). A mathematical model for plasmid replication and distribution in microbial populations. Biotechnology Letters, 11(2), 93-98. doi:10.1007/bf01192181